Key result
In patients with polycystic ovary syndrome, the oral glucose tolerance test identified a higher prevalence of abnormalities of glucose metabolism (31.8%) than fasting plasma glucose alone (16.5%).
Why the study?
What is the prevalence of abnormalities of glucose metabolism in patients with PCOS, and how do ADA and WHO diagnostic criteria compare?
Cross-Sectional (n=85)
What is the prevalence of abnormalities of glucose metabolism in patients with PCOS, and how do ADA and WHO diagnostic criteria compare?
Absolute Event Rate: 31.8% vs 16.5%
In patients with PCOS, OGTT identifies significantly more abnormalities of glucose metabolism than fasting plasma glucose alone, supporting its routine use in this population.
No takes yet. Share an insight, caveat, or question.
OGTT detects more glucose abnormalities than FPG in PCOS; hypothesis-generating for screening impact and requires prospective validation.
Barcellos et al. (2007) conducted a cross-sectional in Polycystic ovary syndrome (PCOS) (n=85). Oral glucose tolerance test (OGTT) / WHO criteria vs. Fasting plasma glucose (FPG) / ADA criteria was evaluated on Prevalence of abnormalities of glucose metabolism (AGM). In patients with polycystic ovary syndrome, the oral glucose tolerance test identified a higher prevalence of abnormalities of glucose metabolism (31.8%) than fasting plasma glucose alone (16.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: